pe for Contract Development and Manufacturing Organizations (CDMOs) has been marked by both headwinds and opportunities. As demand for pandemic

contract development and manufacturing organization (CDMO) services surged during the pandemic, the P/E ratio for CDMOs has been marked by both challenges and opportunities. Here's a detailed analysis: 1. **Impact of Pandemic Demand**: - The COVID-19 pandemic significantly increased demand for vaccine and biologic production capacity. CDMOs, being critical in the manufacturing of biologicals and vaccines, experienced a surge in investments and contracts. - This demand led to high investment in vaccine-related contract manufacturing, with CDMOs and excess capacity pharma manufacturers investing heavily in expanding their production capabilities. 2. **Investment and Capacity Expansion**: - CDMOs have invested in scaling up their production capacity to meet the increased demand. For instance, Lonza has built extra manufacturing lines for Moderna's vaccine, and Univercells and Exye are creating modular facilities for fast production. - These investments are expected to relieve bottlenecks as the pandemic recedes, benefiting the wider biologics manufacturing sector. 3. **P/E Ratio Considerations**: - The P/E ratio for CDMOs, such as Avid Bioservices, has been negative or low due to heavy losses reported in some years. This could be attributed to the high costs associated with rapid capacity expansion and the need to manage supply chain disruptions. - However, a negative or low P/E ratio can also indicate that a company is generating heavy losses compared to its current valuation, which may be expected in a sector experiencing rapid growth and significant investment. 4. **Strategic Collaborations and Acquisitions**: - Strategic moves such as acquisitions can significantly impact a company's stock value and P/E ratio. For example, Avid Bioservices' acquisition by GHO Capital and Ampersand Capital has led to a premium valuation and optimism about future growth. - Such collaborations and acquisitions can lead to a more robust platform for future growth and expansion within the biologics manufacturing sector. 5. **Market Trends and Future Prospects**: - The global Fill Finish Manufacturing Market is projected to grow at a CAGR of 8.9% from 2025 to 2030, reaching $28.14 billion by 2030. This trend is driven by increasing demand for automated and small-batch solutions for personalized medicine manufacturing. - The investment in viral vector manufacturing and bioreactor capacity expansion is expected to continue, benefiting CDMOs and the wider biologics manufacturing sector. In conclusion, the P/E ratio for CDMOs reflects the dual challenges and opportunities presented by the pandemic-driven demand for their services. While the sector has faced significant investment and supply chain pressures, it has also seen strategic investments and acquisitions that position it for future growth. The trend towards personalized medicine and the continued expansion of biologics manufacturing capacity are expected to further shape the sector's trajectory.